학술논문

High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER+ breast cancer.
Document Type
Article
Source
Nature Communications; 11/16/2022, Vol. 13 Issue 1, p1-20, 20p
Subject
CYCLIN-dependent kinase inhibitors
ESTROGEN receptors
BREAST cancer
METASTATIC breast cancer
HORMONE therapy
CANCER patients
P16 gene
Language
ISSN
20411723
Abstract
Copyright of Nature Communications is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)